Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 12.2% After Analyst Upgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was up 12.2% during trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $32.00 to $36.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Day One Biopharmaceuticals traded as high as $17.39 and last traded at $17.26. Approximately 3,653,007 shares traded hands during trading, an increase of 457% from the average daily volume of 656,201 shares. The stock had previously closed at $15.38.

Several other brokerages have also issued reports on DAWN. Piper Sandler reiterated an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a report on Tuesday, February 27th. Finally, Oppenheimer reissued a "market perform" rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $39.83.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the transaction, the chief executive officer now directly owns 721,813 shares of the company's stock, valued at approximately $11,007,648.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now directly owns 1,224,662 shares of the company's stock, valued at approximately $19,729,304.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the completion of the transaction, the chief executive officer now directly owns 721,813 shares in the company, valued at $11,007,648.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,781 shares of company stock valued at $883,160. Corporate insiders own 8.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its position in shares of Day One Biopharmaceuticals by 58.7% during the third quarter. SG Americas Securities LLC now owns 36,980 shares of the company's stock valued at $454,000 after purchasing an additional 13,683 shares during the period. Bank of New York Mellon Corp increased its position in shares of Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company's stock valued at $2,703,000 after purchasing an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Day One Biopharmaceuticals by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company's stock valued at $535,000 after purchasing an additional 8,522 shares during the period. TD Asset Management Inc increased its position in shares of Day One Biopharmaceuticals by 100.0% during the third quarter. TD Asset Management Inc now owns 55,196 shares of the company's stock valued at $677,000 after purchasing an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Day One Biopharmaceuticals by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company's stock valued at $660,000 after purchasing an additional 25,414 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Stock Up 8.2 %

The firm has a market capitalization of $1.45 billion, a P/E ratio of -6.99 and a beta of -1.48. The business has a 50-day moving average price of $15.27 and a 200-day moving average price of $13.78.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). As a group, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.